- Abstract Number: 1757
Bimekizumab Treatment Resulted in Improvements in MRI Inflammatory and Structural Lesions in the Sacroiliac Joints of Patients with Axial Spondyloarthritis: 52-Week Results and Post Hoc Analyses from Two Phase 3 Studies
- Abstract Number: 2352
Bimekizumab Treatment Was Efficacious to 2 Years Regardless of Duration of axSpA Symptoms: Results from Two Phase 3 Studies
- Abstract Number: 2368
Bimekizumab-Treated Patients with Active Psoriatic Arthritis Showed Sustained Improvements in Pain and Fatigue: Up to 2-Year Results from Two Phase 3 Studies
- Abstract Number: 0600
Bimekizumab-Treated Patients with Active Psoriatic Arthritis Showed Sustained Reductions in Disease Impact Assessed by the Psoriatic Arthritis Impact of Disease (PsAID)-12 Questionnaire: Up to 2‑Year Results from Two Phase 3 Studies
- Abstract Number: 0110
Binding Characteristics of Patient Clusters Among Anticardiolipin and Anti-β2-Glycoprotein I ELISA and Non-ELISA Assays: A Survey by the Association of Medical Laboratory Immunologists
- Abstract Number: 1305
Bingo: A Winning Pediatric Rheumatology Teaching Strategy?
- Abstract Number: 1794
Biobehavioral Basis and Outcomes of Cognitive Dysfunction in Childhood Systemic Lupus Erythematosus
- Abstract Number: 0401
Biologic Abatement and Capturing Kids Outcomes and Flare Frequency in Juvenile Spondyloarthritis: Baseline Characteristics and Enrollment
- Abstract Number: 2523
Biological Treatment May Be an Option as First Steroid-Sparing Agent in a Subgroup of Young Takayasu Arteritis Patients with Prominent Acute Phase Reactants and Constitutional Symptoms
- Abstract Number: 2572
Biomarker-guided Treatment-and-stop-strategy for Recombinant IL-1Receptor Antagonist (Anakinra) in Patients with Systemic Juvenile Idiopathic Arthritis
- Abstract Number: 0485
Biomarkers for Disease Activity and Response to Treatment in Early Rheumatoid Arthritis: Metabolomics and Machine Learning Analyses in NORD-STAR Cohort
- Abstract Number: 2387
Biomarkers of Lupus Nephritis Are Less Predictive in APOL1 High Risk Genotype Lupus
- Abstract Number: 0825
Biosimilars of Rituximab in ANCA-associated Vasculitis Compared to the Originator (BRAVO): 6-month Outcomes of a Longitudinal Cohort Study
- Abstract Number: 0837
Bispecific Autoantigen-T Cell Engagers (BaiTE) to Selectively Target Autoreactive B Cells in Antiphospholipid Syndrome
- Abstract Number: 1806
Bisphenol a Methylation Scores Associate with SLE and ClinicalSubphenotypes
- « Previous Page
- 1
- …
- 26
- 27
- 28
- 29
- 30
- …
- 181
- Next Page »